Treatment of non-genotype 1 hepatitis C virus patients

Research output: Contribution to journalArticlepeer-review


The HCV genotype will remain an important, independent pre-treatment predictor of virological response. While direct acting antivirals (DAA) will improve in the coming months the rates of virological response in patients with HCV-1, the development of DAAs effective against other HCV genotypes is at an earlier stage. Therefore, Peg-Interferon and Ribavirin will continue to be used in the near future as standard treatment in these patients. In this manuscript, we will discuss highly debated aspects related to non-1 HCV genotypes. First of all, the predictive role of IL28B genetic variation, secondarily specific aspects related to HCV-4. In the final part, we will highlight potential differences between HCV-2 and HCV-3. Indeed, despite the fact that HCV-2 and HCV-3 have been evaluated together in the majority of studies, HCV-3 patients achieve lower rates of virological response as compared to HCV-2. Whether a genotype individualized treatment may increase virologic response is the object of current investigations.

Original languageEnglish
Pages (from-to)87-93
Number of pages7
JournalCurrent Gastroenterology Reports
Issue number1
Publication statusPublished - Feb 2012


  • Direct acting antivirals
  • HCV genotype 2
  • HCV genotype 3
  • HCV genotype 4
  • Individualized Treatment
  • Peg-IFN
  • Ribavirin
  • Short treatment

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Treatment of non-genotype 1 hepatitis C virus patients'. Together they form a unique fingerprint.

Cite this